Chardan Capital: Maintaining the Dyne Therapeutics (DYN.US) rating, adjusted from buy to buy rating, and adjusted the target price from $31.00 to $42.00.
Chardan Capital：维持Dyne Therapeutics(DYN.US)评级，由买入调整至买入评级, 目标价由31.00美元调整至42.00美元。
Chardan Capital: Maintaining the Dyne Therapeutics (DYN.US) rating, adjusted from buy to buy rating, and adjusted the target price from $31.00 to $42.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.